Present addresses: J. L. Sobell and S. S. Sommer, Division of Molecular Medicine, Beckman Research Institute, City of Hope, 1450 East Duarte Road, Duarte, CA 91010–0269, USA; and Dr H. Li, Rowe Program in Human Genetics, School of Medicine, University of California, Davis, One Shields Avenue, Davis, CA 95616–8500, USA.
The incidence of venous thromboembolism among Factor V Leiden carriers: a community-based cohort study
Version of Record online: 25 JAN 2005
Journal of Thrombosis and Haemostasis
Volume 3, Issue 2, pages 305–311, February 2005
How to Cite
HEIT, J. A., SOBELL, J. L., LI, H. and SOMMER, S. S. (2005), The incidence of venous thromboembolism among Factor V Leiden carriers: a community-based cohort study. Journal of Thrombosis and Haemostasis, 3: 305–311. doi: 10.1111/j.1538-7836.2004.01117.x
- Issue online: 25 JAN 2005
- Version of Record online: 25 JAN 2005
- Received 21 July 2004, accepted 28 September 2004
- Factor V Leiden;
- venous thromboembolism
Summary. While Factor V (FV) Leiden is a risk factor for venous thromboembolism (VTE), the incidence of VTE among FV Leiden carriers is uncertain. The objective of the study was to estimate the overall age-specific and pregnancy-related VTE incidence and the relative risk among FV Leiden carriers. In a community-based sample of 3424 south-eastern Minnesota residents, 230 (6.7%) were genotyped as FV Leiden carriers; 220 carriers (mean age = 68 years) could be matched to a non-carrier on age, gender, ethnicity and length of medical history. We performed a retrospective cohort study of carriers and non-carriers by reviewing the complete medical records in the community for demographic and baseline characteristics, pregnancies and live births, and first lifetime VTE. Over 14 722 person-years, 24 (10.9%) carriers developed VTE [overall incidence = 163 (95% CI 104, 242) per 100 000 person-years]. VTE incidence rates for ages 15–29, 30–44, 45–59 and ≥ 60 years were 0, 61, 244 and 764 per 100 000 person-years, respectively (cumulative VTE incidence at age 65 years = 6.3%). VTE incidence for carriers did not differ significantly from that for non-carriers except for those ≥ 60 years old (relative risk = 3.6; 95% CI 2.0, 6.0). There were 311 live births among 130 women carriers; no VTE events occurred during pregnancy or postpartum [incidence = 0 (95% CI 0, 1186) per 100 000 women-years]. Most FV Leiden carriers do not develop VTE. Among all carriers, those ≥ 60 years old are at the highest risk for VTE. The incidence of VTE among asymptomatic women carriers during pregnancy is low and insufficient to warrant prophylaxis.